The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong picks.Considering these trends, value investing is clearly one of the most preferred ways to find strong stocks in any type of market. Value investors use fundamental analysis and traditional valuation metrics to find stocks that they believe ...

Editor's note: Seeking Alpha is proud to welcome Solomon Oshabaheebwa as a new contributing analyst. You can become one too! Share your best investment idea by submitting your article for review to our editors. Get published, earn money, and unlock exclusive SA Premium access.I am an independent investor and analyst with a background in Biomedical Engineering. Currently pursuing a PhD in the field, I leverage my research skills and biotech expertise to critically assess publicly traded companies, focusing o ...

Company Announcement Net sales of DARZALEX® in the first quarter of 2025 totaled USD 3,237 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; April 15, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by J&J ...

Company Announcement COPENHAGEN, Denmark; April 10, 2025 – Genmab A/S (Nasdaq: GMAB) At Genmab A/S’ Annual General Meeting on March 12, 2025, it was decided to reduce the Company’s share capital with nominally DKK 2,076,853 by cancellation of 2,076,853 of the Company’s holding of shares with a nominal value of DKK 1 each. The share capital reduction has today been registered with the Danish Business Authority. Genmab's share capital will be updated in Nasdaq's system as soon as possible and expectedly on M ...

Company Announcement COPENHAGEN, Denmark; April 7, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program. The share buy-back program is expected to be completed no later than July 10, 2025. The following transactions were executed under the program from March 31 to April 4, 2025: Trading PlatformNo. of sharesAverage price (D ...

Media Release COPENHAGEN, Denmark; March 31, 2025 Genmab A/S (Nasdaq: GMAB) announced today that the European Commission (EC) has granted marketing authorization for TIVDAK (tisotumab vedotin), an antibody-drug conjugate (ADC), as monotherapy treatment for adult patients with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy. TIVDAK is the first and only ADC to be granted European Union (EU) marketing authorization for people living with recurrent or metastatic ce ...

The Japanese Ministry of Health, Labour and Welfare on Thursday approved Genmab A/S’ GMAB Tivdak (tisotumab vedotin) for advanced or recurrent cervical cancer that has progressed on or after cancer chemotherapy.Tivdak is the first and only antibody-drug conjugate (ADC) to be approved for cervical cancer in Japan.The approval is based on data from the Phase 3 innovaTV 301 clinical trial that evaluated the efficacy and safety of TIVDAK compared to chemotherapy in patients with advanced or recurrent cervical c ...

Media ReleaseCOPENHAGEN, Denmark; March 27, 2025 TIVDAK® is the first and only antibody-drug conjugate (ADC) approved for patients with advanced or recurrent cervical cancer in JapanApproval is based on results from the global Phase 3 innovaTV 301 trial, in which TIVDAK demonstrated superior overall survival compared to chemotherapyRising cervical cancer incidence and mortality rates in Japan signify need for new treatment options Genmab A/S (Nasdaq: GMAB) today announced that the Japan Ministry of Health, ...

Company Announcement Repurchase of up to 2.2 million shares with a maximum aggregate total value of DKK 4.0 billionReduce the capital of Genmab and honor our commitments under the Restricted Stock Unit programCompletion expected no later than July 10, 2025 COPENHAGEN, Denmark; March 25, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that it is initiating a share buy-back program, to reduce capital and to honor our commitments under the Restricted Stock Unit program. The share buy-back program will be und ...

Core Viewpoint - AbbVie Inc. has filed a lawsuit against Genmab A/S and others, alleging misappropriation of trade secrets related to disaccharides used in antibody-drug conjugates (ADCs) [1][2][3] Group 1: Legal Proceedings - AbbVie is seeking damages and broad injunctive reliefs, claiming that Genmab and others have misappropriated its trade secrets [2] - Genmab categorically refutes the allegations and intends to vigorously defend against AbbVie's claims [2][3] - This lawsuit is part of a series of recent legal actions by AbbVie against competitors for similar allegations [3] Group 2: Product Information - The complaint pertains to Rina-S™, a clinical-stage ADC targeting FRα, currently in Phase 3 development for ovarian cancer and other solid tumors [4] - Rina-S™ utilizes a proprietary antibody and a unique linker to achieve a drug-to-antibody ratio (DAR) of 8 for the payload, exatecan [4] - Genmab aims to broaden the development plans for Rina-S™ based on ongoing clinical trial data, potentially addressing a wider patient population in ovarian cancer [5] Group 3: Company Overview - Genmab is an international biotechnology company focused on developing innovative antibody-based medicines [6][9] - The company has a strong track record in the discovery and commercialization of differentiated antibody therapeutics [6] - Genmab's vision by 2030 is to transform the lives of patients with cancer through advanced antibody medicines [9]